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(Nottingham Health Proﬁle (NHP) and EQ-5D) outcome assess-
ments in PH. METHODS: PH patients completed the instru-
ments in a postal survey. Instruments were compared in terms of
end effects, association with clinical indicators (Six Minute Walk
Test (6MWT) and New York Heart Association class (NYHA))
and ability to discriminate between patients on the basis of
symptom severity and perceived general health. RESULTS:
In total, 91 patients participated (mean (SD) age: 52.6 (16.0),
64% female, mean (SD) duration of PH: 4.8 (6.0) years). End
effects were slight in the CAMPHOR (Energy scale = 10.1%
ﬂoor/11.2% ceiling; Mood 19.3% ﬂoor) but substantial in the
NHP. NHP ﬂoor effects ranged from 54.9% (Pain) to 11.9%
(Physical Mobility) and ceiling effects from 32.5% (Energy) to
0.0% (Pain and Social). NYHA correlations with the NHP
ranged from 0.59 (Physical Mobility) to 0.20 (Pain) and with the
CAMPHOR from 0.60 (Functioning) to 0.47 (Overall Symp-
toms). 6MWT distance correlated 0.71 with CAMPHOR Func-
tioning. All CAMPHOR, NHP (except Sleep) and EQ-5D scales
discriminated between patients based on perceived general health
(p < 0.01). The scales also distinguished between patients accord-
ing to symptom severity (p < 0.01). All CAMPHOR scales
(except Mood) distinguished between NYHA classiﬁcations (p £
0.001). Of the generic measures only the NHP Energy and 
Physical Mobility scales discriminated according to NYHA.
CONCLUSIONS: The CAMPHOR had fewer end effects,
showed closer association with clinical indicators and greater
sensitivity to NYHA class than the generic measures and is 
therefore recommended for assessing outcome in PH.
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OBJECTIVES: To assess the prevalence, awareness, treatment,
and control of hypercholesterolemia among the Chinese Ameri-
cans in New York City. METHODS: This is a community-based
cross-sectional cohort study. Certiﬁed nurses conducted cardio-
vascular disease screenings among 456 Chinese Americans, 64%
women, aged 18 years or older in 2003. Serum total cholesterol
concentration was obtained. Risk factors such as smoking, exer-
cise, blood pressure, body mass index, and waist-to-hip ratio
were also recorded. Hypercholesterolemia is deﬁned as serum
total cholesterol concentration equal to or greater than 200
mg/dL or reported using cholesterol-lowering medications.
Hypercholesterolemia awareness and treatment were assessed
with standardized questions. RESULTS: The age-adjusted 
mean total cholesterol concentration in all study subjects was
198mg/dL (95% CI, 194.28, 200.81) and the prevalence of
hypercholesterolemia in our sample was 56%. Hypercholes-
terolemia awareness, pharmacologic treatment, and control on
pharmacologic treatment were 43%, 16%, and 6%, respectively.
Non-pharmacologic treatment alone accounted for 7%. In a
Pearson correlation analysis, increasing age (p = 0.047) and
blood pressure (both diastolic and systolic, p < 0.001) were inde-
pendently associated with increased rates of serum concentration
of cholesterol; increasing body mass index, waist-to-hip ratio,
exercise, and smoking are not associated with increased in serum
total cholesterol concentrations. CONCLUSIONS: The ﬁndings
suggest that expanded effort is needed to improve hypercholes-
terolemia awareness, treatment, and control. Practitioners may
need to take a more aggressive stance in screening and treating
patients with lipid disorders- with or without existing coronary
heart disease.
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OBJECTIVES: To describe the impact on real conditions of a
treatment’s compliance. METHODS: Between May and July,
2002, 567 GP recruited 1049 female patients spontaneously con-
sulting for CVD. The patients ﬁlled in questionnaires (CIVIQ,
SF12 and Epworth) in order to evaluate the consequences of their
disease. A patients subgroup with RA (treated with ruscus
aculeatus, hespéridine méthyl chalcone HMC & acide ascor-
bique Vit.C ) prescription was identiﬁed. RESULTS: The group
with 2 tablets a day (n = 135) was called the << “non observant
group”: (NOG) >>, the group treated with the recommended
dosage (4 tablets) a day was called “ ‘observant group’: (OG)”
(n = 831). Before treatment, both groups were comparable in
terms of average age (44.1 vs. 45), height and weight (BMI : 24.3
vs. 24.2). The risk factors have been compared: sedentary
lifestyle, family history, underﬂoor heating, pregnancy. None are
signiﬁcant except sedentary lifestyle (NOG 55% vs. 0:66%, p <
0.0001, test ki2). No signiﬁcant difference was observed between
the NOG and the OG: CIVIQ : 34.3 v. 32 , SF12: Physical dimen-
sion: 48.2 v. 46.2, Mental Dimension: 42.5 v. 45, Epworth: 7.2
v. 7.8. After a seven day treatment, the same scales were admin-
istered, in the NOG, no QoL scale improved. In the OG, SF-12
Mental dimension, CIVIQ and Epworth scores signiﬁcantly
improved at D7 (with p respectively < 0.001, = 0.01, < 0.001).
CONCLUSIONS: The compliance with treatment at recom-
mended dosage clearly shows an improvement of speciﬁc and
non speciﬁc quality of life scales at seven days. The future avail-
ability of an RA double dose tablet should improve treatment’s
compliance by decreasing the intakes.
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CVD treatment is based on a double treatment, either conven-
tional (contention or venotonics) or radical (sclerotherapy,
surgery). OBJECTIVES: Describing the venotonic and con-
tention association impact on the patients quality of life.
METHODS: Between May and July, 2002, 567 GP’s recruited
1045 female patients spontaneously consulting for CVD. Two
patient subgroups were identiﬁed: RA (treated with ruscus
aculeatus, hespéridine méthyl chalcone HMC & acide ascor-
bique Vit.C), RAC: (treated with RA and contention). RESULTS:
In both subgroups RA (n = 697) and RAC (n = 269), risk factors
were compared: sedentary lifestyle, family history, underﬂoor
heater, pregnancy. Obesity and family history were found most
often among the RAC patients (25% v. 16% and 50% v. 34%,
p < 0.001 ki2). At inclusion, speciﬁc (CIVIQ), non speciﬁc (SF12)
quality of life (QoL) and daytime sleepiness (Epworth scale) were
evaluated through a self-questionnaire. A total of 304 patients
answered at D0 and D7. No signiﬁcant difference was observed
between the 2 groups RAC v. RA; CIVIQ: 32.3 v. 32.3, SF12:
Physical dimension: 45 v. 46.9, Mental dimension: 43.7 v. 45,
Epworth: 8.4 v. 7.5. After a 7-day treatment, the same scales
were administered. In the RAC group, CIVIQ improved (p =
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0.0004). In the RA group SF12 Mental Dimension, CIVIQ and
Epworth signiﬁcantly improved at D7 versus D0 with respec-
tively p < 0.001, =0.036, p < 0.001). CONCLUSIONS: In the
chronic venous disease, associating a contention to a venotonic
prescription does not improve the patient’s quality of life.
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Many studies have conﬁrmed obesity as a Chronic Venous
Disease (CVD) risk factor. Few studies have described the pathol-
ogy through Body Mass Index (BMI). OBJECTIVES: To describe
the impact of obesity in CVD. METHODS: Between May and
July, 2003, 567 GP’s recruited 1049 female patients sponta-
neously consulting for CVD. The patients ﬁlled in a series of 
validated questionnaires in order to evaluate the consequences
of their disease. RESULTS: The results of the study concern 
1045 patients with a mean age of 44–45 years old (SD 10.70)
(min: 18–max: 65); 66% with a professional activity. The
patients average size was 164.39cm (SD 5.99) for an average
weight of 65.2kg (SD 12.5). The BMI calculation gives an
average BMI of 24.17 (SD 4.71). The values issued by the WHO
have been taken into account: Thinness: 4%—Normal weight
62%—Overweight: 24%—Obesity: 10%. For each of these sub-
groups, CIVIQ score is respectively of 21.2–16.6–25.8–32.1. In
order to make the analysis easier, we have reduced the two sub-
groups BMI <27 vs.> 27. CIVIQ score is: 29.8 vs. 40.9 (p <
0.0001). This difference is found through the severity (CEAP)
classiﬁcation: 15% of C0–C2 have a BMI > 27, while they rep-
resent 26% of the C3–C6 (p < 0.001). We have tested both sub-
groups on sedentary lifestyle, family history, underﬂoor heating
and pregnancy risk factors. None are signiﬁcant except seden-
tary lifestyle (61% vs. 76%, p < 0.0001). CONCLUSIONS: A
more important CVD severity grade is expected for a BMI > 27.
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OBJECTIVES: Despite the proven efﬁcacy of antihypertensive
drugs (antiHTN) on morbidity and mortality, the extent of
undertreatment and non-persistence is extremely high, hamper-
ing their effectiveness in real-life. In order to assess drug utiliza-
tion patterns of newly treated hypertensive patients, we
estimated the 1-year risk of stopping initial treatment, the fre-
quency of patients requiring add-on or switch therapy with other
antiHTN. METHODS: A retrospective cohort study was con-
ducted using Health Search Database that provided data by 320
Italian general practitioners. All newly-diagnosed hypertensive
patients aged ≥ 35 years, who received antiHTN during the ﬁrst
three months after diagnosis were identiﬁed and were catego-
rized into one of the following groups: 1) Continuers: patients
continuing the ﬁrst class of antiHTN; 2) Combiners: patients
receiving an add-on with another class; 3) Switchers: 
patients changing from the ﬁrst medication to another type of
antiHTN; and 4) Discontinuers: patients stopping the ﬁrst type
therapy. RESULTS: Overall, among 13,303 new hypertensives,
19.8% were continuers, 22.1% combiners, 15.5% switchers,
and 42.6% discontinuers. The highest proportion of continuers
was found for persons starting with angiotensin-II antagonists
(ARB’s) (25.2%), calcium-antagonists (CCB’s) (23.9%), and
ACE-inhibitors (23.3%). Starting on diuretics was associated
with the highest risk of discontinuing treatment, while the lowest
risk was associated with starting on ARB’s (Hazard Ratio [HR]:
0.43; 95% Conﬁdence Interval (CI): 0.40–0.47), ACE-inhibitors
(HR: 0.50; CI: 0.47–0.53) and CCB’s (HR: 0.55; CI: 0.52–0.59).
The risk of receiving add-on therapy was associated with a
longer duration of therapy. Patients starting with alfa-blockers
had the highest risk of switching therapy (HR: 0.50; CI:
0.47–0.53), while patients starting on ARB’s (HR: 0.51; CI:
0.42–0.62) or ACE-inhibitors (HR: 0.60; CI: 0.52–0.69) had the
lowest risk. CONCLUSIONS: In this cohort the persistence to
initial antiHTN is rather low and the need to combine several
drugs is often required.
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A major factor why hypertension is often insufﬁciently con-
trolled is due to poor medication adherence. The AdhereRx is a
web-based technology that can assist practitioners in educating
patients on the importance of medication adherence. The
Morisky scale is a simple validated tool that can detect patient
non-adherence to medications. OBJECTIVES: Assess patient
medication compliance and hypertension goal achievement using
the Morisky survey along with education resources included in
the AdhereRx program. METHODS: This study was undertaken
in a hospital outpatient pharmacy. Patient presented with an
antihypertensive medication prescription was asked to complete
the Morisky survey. Results were entered into the AdhereRx
website. The most recent blood pressure measurement was
recorded. Based on the Morisky score, the pharmacist browsed
the online library and provided appropriate printed educational
materials from the website in conjunction with individual verbal
counseling to the patient. RESULTS: Of the 91 men and women
with a mean age of 57.56 (standard deviation, 12.09) years, 21%
had low to medium level and 79% had a high level of medica-
tion adherence. The most common reason patients stopped
taking their medication was “forgot to take their medication”
followed by “careless”, followed by “stop medication when feel
better” and “stop medication when feel worse”. More patients
in the high adherence group achieved blood pressure goal than
patients who scored low or medium adherence, 83% vs. 63%
respectively (p < 0.001). Patients who had low adherence
required more antihypertensive agents to control their blood
pressure. In a Pearson correlation analysis, high medication
adherence is associated with increased rates of blood pressure
goal attainment (p < 0.01). CONCLUSIONS: There is a strong
positive correlation between medication adherence and blood
pressure goal attainment. The AdhereRx web-based program is
easy to use and provides speciﬁc tools to help practitioners
educate their patients to improve medication adherence.
